Drugs / Muscadine Plus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03535675 | Oct 2018 → Jul 2022 | prostate adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Muscadine Plus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03535675 ↗ |
| Route | Oral | “once daily oral dosing of 4000 mg Muscadine Plus” NCT03535675 ↗ |